醫(yī)學(xué)全在線
醫(yī)學(xué)全在線首頁(yè)-醫(yī)師-藥師-護(hù)士-衛(wèi)生資格-高級(jí)職稱(chēng)-考試題庫(kù)-網(wǎng)校-考研-圖譜-下載-招聘  
分類(lèi)
國(guó)家級(jí)省級(jí)浙江省各省雜志
科技核心北大核心CSCDCSCD擴(kuò)展
工具
期刊知識(shí)寫(xiě)作指導(dǎo) 論文投稿推薦期刊
期刊驗(yàn)證論文檢測(cè) 錄用通知往期目錄
SCI
SCI指導(dǎo)影響因子
期刊點(diǎn)評(píng)基金動(dòng)態(tài)
其它
經(jīng)濟(jì)教育計(jì)算機(jī)
建筑體育農(nóng)業(yè)
北京|天津|河北|山西|湖北|江蘇|安徽|山東|上海|浙江|江西|福建|湖南|寧夏|內(nèi)蒙古|河南
四川|重慶|貴州|云南|遼寧|吉林|廣東|廣西|海南|陜西|甘肅|新疆|青海|衛(wèi)生部直屬|黑龍江|兵團(tuán)
您現(xiàn)在的位置: 醫(yī)學(xué)全在線 > 醫(yī)學(xué)論文 > 論文投稿 > 正文:醫(yī)學(xué)免費(fèi)論文:TACE、PEI雙介入間隔療法治療晚期原發(fā)性肝細(xì)胞癌臨床觀察
    

醫(yī)學(xué)免費(fèi)論文:TACE、PEI雙介入間隔療法治療晚期原發(fā)性肝細(xì)胞癌臨床觀察

來(lái)源:本站原創(chuàng) 更新:2013-10-9 論文投稿平臺(tái)

醫(yī)學(xué)免費(fèi)論文:TACE、PEI雙介入間隔療法治療晚期原發(fā)性肝細(xì)胞癌臨床觀察

【摘要】  目的 對(duì)照觀察肝動(dòng)脈化療栓塞(transcatheter arterial chemoembolization,TACE)和經(jīng)皮肝穿刺無(wú)水乙醇注射(percutaneous ethanol injection,PEI)雙介入間隔療法治療晚期原發(fā)性肝細(xì)胞癌(hepatocellular carcinoma,HCC)臨床效果。方法 觀察組25例采用間隔2周進(jìn)行TACE、PEI分別配合治療,每療程TACE 2~3次、PEI 2~4次。對(duì)照組29例單純進(jìn)行TACE治療。兩組觀察期3年。結(jié)果 觀察組1年內(nèi)生存率與對(duì)照組相比無(wú)明顯差異,2年、3年內(nèi)生存率高于對(duì)照組(P<0.05);觀察組腫瘤縮小總有效率高于對(duì)照組(P<0.05)。結(jié)論 TACE、PEI間隔雙介入療法較單純TACE治療晚期原發(fā)性肝細(xì)胞癌能夠提高治療效果,延長(zhǎng)患者存活時(shí)間,改善生存質(zhì)量。

【關(guān)鍵詞】  原發(fā)性肝細(xì)胞癌; 肝動(dòng)脈化療栓塞術(shù); 經(jīng)皮肝穿刺無(wú)水乙醇注射

Clinical observation of treating the primary hepatocellular carcinoma in the advanced stage by using TACE and PEI  ZHONG Liqing,XU yincong,LU longhui,et al.Department of Xray,the 123rd Hospital of PLA,Bengbu  233015,China醫(yī).學(xué).全.在.線quanxiangyun.cn

【Abstract】  Objective  To comparatively observe the clinical efficacy of transcatheter arterial chemoembolization(TACE) combined with percutaneous ethanol injection (PEI)in the treatment of primary hepatocellular carcinoma (HCC) in the advanced stage. Methods  The observation group (25 cases) were treated with TACE and PEI with intervals about two weeks. Each course of treatment included 2 to 3 times of TACE and 2 to 4 times of PEI.The control group (29 cases) were treated only with TACE. All the two groups were observed for 3 years. Results  The survival rate of the two groups had no remarkable difference in one year, but the survival rate of observation group was higher than that of the control group in two or three years(P<0.05).The total effective rate of tumor reduction in the observation group was higher than that of the control group(P<0.05). Conclusion  Compared with the single TACE treatment, TACE combined with PEI treatment for the advanced primary HCC can improve the therapeutic efficacy and extend the survival time and improve the quality of life of patients.

【Key words】  Primary hepatocellular carcinoma;Transcatheter arterial chemoembolization;Percutaneous ethanol injection

對(duì)于不能手術(shù)切除的晚期原發(fā)性肝細(xì)胞癌(hepatocellular carcinoma ,HCC),目前采用的姑息療法是肝動(dòng)脈化療栓塞(transcatheter arterial chemoembolization,TACE)和經(jīng)皮肝穿刺無(wú)水乙醇注射(percutaneous ethanol injection,PEI)。我院采用TACE、PEI間隔療法治療HCC患者25例,取得較好療效。


[1] [2] [3] [4] 下一頁(yè)

...
關(guān)于我們 - 聯(lián)系我們 -版權(quán)申明 -誠(chéng)聘英才 - 網(wǎng)站地圖 - 網(wǎng)絡(luò)課程 - 幫助
醫(yī)學(xué)全在線 版權(quán)所有© CopyRight 2006-2046, MED126.COM, All Rights Reserved
浙ICP備12017320號(hào)
百度大聯(lián)盟認(rèn)證綠色會(huì)員實(shí)名網(wǎng)站 360認(rèn)證可信網(wǎng)站 中網(wǎng)驗(yàn)證